SecBot SecBot
144 ·Filed Apr 10, 2026

TSHA

Taysha Gene Therapies, Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed7mo ago SEC0001974158-26-000040
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

Monitor for actual sales near the January 12, 2026 date; since this is under a pre-established 10b5-1 plan, it carries less negative signal than an ad-hoc sale, but traders should still watch for execution as it may coincide with other catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$4.42
T+0 close · Apr 10, 2026 · via day close
Latest settled
+46.83%
T+60 · $6.49
Vs SPY
+37.91%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $4.42entry
  2. T+1 · 7mo ago +6.56%α +5.35% · $4.71
  3. T+5 · 7mo ago +46.15%α +42.86% · $6.46
  4. T+20 · 6mo ago +54.30%α +46.57% · $6.82
  5. T+60 · 4mo ago +46.83%α +37.91% · $6.49
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Nagendran Sukumar, an officer of Taysha Gene Therapies, filed a Form 144 to notify intent to sell up to 200,000 shares of common stock, valued at approximately $942,740, under a 10b5-1 selling plan adopted on June 11, 2025. The sale is scheduled for January 12, 2026.

Key Facts

  • Reporting person: Nagendran Sukumar, officer of TSHA
  • Number of shares proposed for sale: 200,000
  • Approximate value of shares: $942,740
  • Sale date: January 12, 2026
  • Sales to be executed under a 10b5-1 plan adopted on June 11, 2025
  • Shares are common stock issued from prior RSU and stock option grants

Financial Impact

Approximately $942,740 in potential near-term selling pressure from an insider, representing a small fraction of TSHA's $1.3B market cap.

insider ownershipshare float

Risk Factors

  • Potential perception of insider selling ahead of earnings or clinical trial readouts
  • Execution of sale could contribute to short-term downward price pressure if market conditions are weak

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001974158-26-000040
Document: 0001974158-26-000040-index.html0001974158-26-000040
Document: 0001974158-26-000040.txt0001974158-26-000040

Track record

14 reports on TSHA

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +20.50% at T+60 after the Jun 25, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 10, 2026